|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, ectopic of DRG1 reduces taxol induced apoptosis of lung adenocarcinoma cells.
|
27626498 |
2016 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These studies highlight the expanding role of DRG1 in tumorigenesis and reveal a mechanism of DRG1 in taxol resistance.
|
27626498 |
2016 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data suggest that DRG-1 plays an important role in melanoma cell growth and transformation, indicating that DRG1 may represent a novel target for CD4(+) T cell-mediated immunotherapy in melanoma.
|
25993655 |
2015 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
N-myc downstream regulated gene 1 (NDRG1/Cap43/Drg-1) has previously been shown to be dysregulated in esophageal squamous cell carcinoma (ESCC).
|
23192272 |
2013 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.
|
22481237 |
2012 |
|
Prostatic Intraepithelial Neoplasias
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CD44s is decreased in both PIN and cancer; Drg-1, E-cadherin, KAI-1, RKIP, and SSeCKS show similar expression between benign epithelia and PIN, but are downregulated in invasive cancer; whereas, maspin, MKK4, Nm23 and PTEN are upregulated in PIN and downregulated in cancer.
|
22886631 |
2012 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.
|
22481237 |
2012 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.
|
22481237 |
2012 |
|
Tumor Angiogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.
|
22481237 |
2012 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aberrant localization patterns of Cx-26 and Drg-1 were observed in bladder tumors.
|
18288642 |
2008 |
|
Immunologic Deficiency Syndromes
|
0.010 |
Biomarker
|
group |
BEFREE |
The tumor metastasis suppressor gene Drg-1 has been shown to suppress metastasis without affecting tumorigenicity in immunodeficient mouse models of prostate and colon cancer.
|
17178897 |
2006 |
|
Secondary malignant neoplasm of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that the expression of the Drg-1 protein was significantly reduced in breast tumor cells, particularly in patients with lymph node or bone metastasis as compared to those with localized breast cancer.
|
15184886 |
2004 |
|
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
The downregulation of the Drg-1 gene appeared to be largely at the RNA level, and the DNA methylation inhibitor, 5-Azacytidine, significantly elevated the Drg-1 gene expression in various breast tumor cell lines.
|
15184886 |
2004 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The downregulation of the Drg-1 gene appeared to be largely at the RNA level, and the DNA methylation inhibitor, 5-Azacytidine, significantly elevated the Drg-1 gene expression in various breast tumor cell lines.
|
15184886 |
2004 |
|
Secondary malignant neoplasm of liver
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Functional studies revealed that overexpression of Drg-1 in metastatic colon cancer cells reduced in vitro invasion through Matrigel and suppressed in vivo liver metastases in nude mice.
|
10676663 |
2000 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Functional studies revealed that overexpression of Drg-1 in metastatic colon cancer cells reduced in vitro invasion through Matrigel and suppressed in vivo liver metastases in nude mice.
|
10676663 |
2000 |
|
Squamous cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The absence of Drg1 induction in growth-inhibited A431 epidermoid carcinoma cells indicates that Drg1 up-regulation in colon carcinoma cells is not a result of decreased proliferation.
|
9251681 |
1997 |
|
ADENOMAS AND ADENOCARCINOMAS
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Compared to normal colon mucosa, Drg1 mRNA expression is decreased in colon adenomas and adenocarcinomas.
|
9251681 |
1997 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Methylselenocysteine/CPT-11 treatment, compared with CPT-11 alone, resulted in a significant decrease in levels of ABCC1 and DRG1 in FaDu tumors and an increase in levels of CYP3A5 and TNFSF6 in A253 tumors.
|
15897249 |
2005 |
|
Prostatic Neoplasms
|
0.020 |
Biomarker
|
group |
LHGDN |
The Drg-1 gene suppresses tumor metastasis in prostate cancer.
|
12702552 |
2003 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Similarly, tumors established from Drg1 overexpressing SW620 cells were more resistant to CPT-11 as compared with tumors established from vector-transfected SW620 cells in mice.
|
12124325 |
2002 |
|
Prostatic Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
One of the genes markedly upregulated by androgens proved to be identical to differentiation-related gene 1 (Drg1; also described as RTP, Cap43 and rit42), a gene whose expression has recently been shown to be diminished in colon, breast and prostate tumors.
|
10428464 |
1999 |
|
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
However, the molecular basis of DRG1 in cell proliferation regulation and the relationship between DRG1 and tumor progression remain poorly understood.
|
27626498 |
2016 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
CD44s is decreased in both PIN and cancer; Drg-1, E-cadherin, KAI-1, RKIP, and SSeCKS show similar expression between benign epithelia and PIN, but are downregulated in invasive cancer; whereas, maspin, MKK4, Nm23 and PTEN are upregulated in PIN and downregulated in cancer.
|
22886631 |
2012 |
|
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
The proteins that were overexpressed are cancer inhibitors (NME, DRG1, IL10), enhancers (SOD2, FAK, IL17, and CREB), and proteins that suppress cancer progression in cells of some cancers and promote it in others (FUT1, integrin beta3, serpin E1, TIAM1, and claudin 4).
|
21344390 |
2011 |